Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial

Background Dose-dense sequential chemotherapy with anthracyclines and taxanes achieved an 18% reduction of recurrence risk in early breast cancer (BC). The optimal chemotherapy schedule and interval between cycles remain under investigation. Methods Overall, 990 patients were randomised to receive e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2022-09, Vol.127 (4), p.695-703
Hauptverfasser:	Zagouri, Flora, Koliou, Georgia-Angeliki, Dimitrakopoulos, Foteinos, Papadimitriou, Christos, Binas, Ioannis, Koutras, Angelos, Papakostas, Pavlos, Markopoulos, Christos, Venizelos, Vasileios, Xepapadakis, Grigorios, Andrikopoulou, Αngeliki, Karanikiotis, Charisios, Psyrri, Amanda, Bafaloukos, Dimitrios, Kosmidis, Paris, Aravantinos, Gerasimos, Res, Eleni, Mauri, Davide, Koumarianou, Anna, Petraki, Kalliopi, Tsipoura, Anna, Pectasides, Dimitrios, Gogas, Helen, Fountzilas, George
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4028/67/1347 692/699/67/1347 Anthracycline Antineoplastic Combined Chemotherapy Protocols - adverse effects Australia Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms Cancer Research Chemotherapy Chemotherapy, Adjuvant Clinical trials Cyclophosphamide - adverse effects Disease-Free Survival Drug Resistance Epidemiology Epirubicin Epirubicin - adverse effects ErbB-2 protein Female Fluorouracil - adverse effects Humans Molecular Medicine Monoclonal antibodies Oncology Paclitaxel Paclitaxel - adverse effects Patients Survival Targeted cancer therapy Trastuzumab Trastuzumab - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!